Trial Profile

A First-in-Human Study of the Safety of Single Continuous Intravenous Infusions of CXL-1427 for up to 48 Hours in Healthy Volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 16 Feb 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cimlanod (Primary)
Indications Decompensated heart failure
Focus Adverse reactions; First in man
Sponsors Cardioxyl Pharmaceuticals

Most Recent Events

31 Jan 2019 Results published in the Journal of Clinical Pharmacology
28 Jul 2014 Positive results have been reported in a Cardioxyl Pharmaceuticals media release.
28 Jul 2014 Status changed from recruiting to completed, according to a Cardioxyl Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com